Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist
29.1.2021 17:03:00 EET | Business Wire | Press release
Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% survival rate at explant. A majority of surviving patients recovered their native heart function without needing further mechanical support or a heart transplant.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210129005016/en/
Impella 5.5 with SmartAssist pulls blood from the left ventricle through an inlet area near the tip of the pump and expels blood through the catheter into the ascending aorta. (Graphic: Business Wire)
The study is the first large, multicenter experience examining survival rates with Impella 5.5 with SmartAssist support. It was presented at The Society of Thoracic Surgeons (STS) 2021 Annual Meeting by lead author Edward Soltesz, MD, MPH, a cardiovascular and heart transplant surgeon at Cleveland Clinic’s Miller Family Heart, Vascular & Thoracic Institute. The data was obtained from the Impella Quality (IQ) database and examined centers with ten or more patients treated with Impella 5.5 with SmartAssist.
The authors conclude Impella 5.5 with SmartAssist demonstrates successful clinical and device outcomes, including:
- 79% overall patient survival rate (n=301)
- 86% survival for cardiomyopathy cardiogenic shock patients (n=141)
- 67% survival for AMI cardiogenic shock patients (n=88)
- 68% survival for postcardiotomy cardiogenic shock patients (n=34)
“We were able to achieve a 79% overall survival rate by taking a novel approach in supporting these critically ill patients,” said Dr. Soltesz. “I am looking forward to seeing more prospective studies around this minimally invasive, high-flow temporary device.”
“This report demonstrates the benefit of the significant unloading with Impella 5.5 use in cardiogenic shock patients. We are impressed with the improved survival rates seen with Impella 5.5 use compared to traditional therapies,” said Scott Silvestry, MD, co-author of the study and surgical director of thoracic transplant, thoracic and cardiovascular surgery at AdventHealth in Orlando. “The use of best practices, techniques and this innovative new technology allows us to provide a better outlook to our patients.”
The STS study presentation provides additional evidence of improved outcomes with use of Impella 5.5 with SmartAssist. A study published in July in the American Society for Artificial Internal Organs (ASAIO) Journal found 84% survival to explant for Impella 5.5 with SmartAssist patients in cardiogenic shock and other challenging cardiac conditions. 76% of those patients achieved native heart recovery. The study examined the outcomes of the first 55 patients treated with Impella 5.5 with SmartAssist at Cleveland Clinic, Hackensack University Medical Center/Hackensack Meridian Health and Cedars-Sinai Medical Center.
In 2019, Impella 5.5 with SmartAssist received the U.S. Food and Drug Administration’s (FDA) highest level of approval for safety and efficacy in the therapy of cardiogenic shock for up to 14 days. Impella 5.5 with SmartAssist delivers peak flows of greater than 6 liters per minute. Benefits of the Impella 5.5 with SmartAssist include:
- Impella Connect, providing cloud-based remote monitoring
- Ease of insertion, via the axillary artery or ascending aorta
- Designed for long-duration support, with patient ambulation, ceramic bearings and no pigtail
- Forward flow with maximum unloading, to provide end organ and coronary perfusion and allow the heart to rest
- Enables heart recovery, as a minimally invasive, weanable VAD
- Ease of patient management, can be intelligently positioned, weaned and managed with SmartAssist
In August, 2020, the FDA granted all left-sided Impella heart pumps, including Impella 5.5 with SmartAssist, an emergency use authorization (EUA) to treat certain patients with COVID-19-related complications who are undergoing extracorporeal membrane oxygenation (ECMO) treatment in the United States.
Attendees of STS 2021 are invited to attend two symposia related to Impella 5.5 with SmartAssist:
- Role of Surgeon: Managing the Shock Patient and Escalation, presented by Zain Khalpey, MD, PhD, from Northwest Medical Center in Tucson. This symposium will take place on Friday, January 29, from 3:30 – 4:00pm EST.
- Post Cardiotomy Cardiogenic Shock (PCCS): Is it Time for a New Strategy?, moderated by Scott Silvestry, MD, from AdventHealth Orlando and featuring a panel discussion with Zain Khalpey, MD, PhD, from Northwest Medical Center in Tucson, Masahiro Ono, MD, PhD, from Methodist Hospital in San Antonio, Danny Ramzy, MD, from Cedars-Sinai Medical Center in Los Angeles, and Deane Smith, MD, from NYU Langone Health in New York City. This symposium will take place on Sunday, January 31, from 7:30 – 8:30am EST.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella Left Ventricular (LV) Support Systems are also authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0 and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac decompensation from myocarditis while on V-V ECMO support. The authorized Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella RP and Impella LV Support Systems have been authorized for the above emergency use by FDA under an EUA and have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210129005016/en/
Contact information
Media Contact:
Sarah Karr
Communications Manager
978-882-8211
skarr@abiomed.com
Investor Contact:
Todd Trapp
Vice President and Chief Financial Officer
(978) 646-1680
ttrapp@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns18.11.2026 10:01:00 EET | Press release
Nearly three in four organizations (72%) have delayed, scaled back or paused an AI or edge project in the past 12 months over concerns about network resilience, according to new research from Opengear, a Digi International company (NASDAQ: DGII) (www.digi.com). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118888190/en/ 72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns The same research shows how the best-prepared organizations fare. Organizations with embedded network resilience, meaning they can reach and recover critical infrastructure when the primary network is down, reported estimated average outage costs $6 million lower over the past 12 months than organizations with less developed resilience capabilities ($12.4 million versus $18.8 million). The advantage extends beyond outages to deployment, routine operations, and incident readiness. Concern reaches organiza
SWISSto12 Selects DLR GSOC as Flight Dynamics Software Partner to Support Upcoming HummingSat Satellite Missions18.11.2026 10:00:00 EET | Press release
SWISSto12, one of the world’s fastest-growing satellite and aerospace companies, today announced it has contracted the German Aerospace Center (DLR) to serve as the company’s primary flight dynamics software provider across its upcoming HummingSat GEO satellite missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118073472/en/ SWISSto12 has selected DLR’s GSOC as its primary flight dynamics software provider for upcoming HummingSat GEO satellite missions. Under this agreement, GSOC will deliver capabilities that span orbit determination, propagation, manoeuvre planning and calibration, orbit events, antenna pointing, and long-term mission analysis. The collaboration is designed to standardise flight dynamics across SWISSto12 programmes, using a heritage European solution integrated into the company’s ground segment architecture. GSOC is part of the DLR Space Operations and Astronaut Training institution in Oberpfaffen
Abbove Brings European Wealth Planning Into the AI Era18.11.2026 09:05:00 EET | Press release
Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors and their client families, it captures what aggregation alone cannot: goals, life events, gifts, the full picture of the family
Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 07:00:00 EET | Press release
Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global report features exclusive editions for the U.S., Canada, Europe, and APAC markets, offering region-specific i
Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 06:30:00 EET | Press release
Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is already taking shape, but scaling it requires more than innovation. Merchants need confidence in who they're transacting with, and payment providers need to know these transactions can move securely and reliably through existing infrastructure," said Rubail Birwadker, SVP, Growth Products & Partnerships, Visa. "No one company can solve tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
